Amgen Inc. (AMGN)
| Previous close | 314.54 |
| Open | 314.11 |
| Bid | 314.35 x 100 |
| Ask | 314.91 x 100 |
| Day's range | 311.90 - 316.67 |
| 52-week range | 211.71 - 329.72 |
| Volume | |
| Avg. volume | 2,752,409 |
| Market cap | 168.821B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 44.89 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.00 (2.86%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- PR Newswire
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared
- PR Newswire
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verificatio
- PR Newswire
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice president of Research and Development and chief
